VXRT News and Press, Vaxart Inc. From 07/06/20

Introduction Vaxart ( VXRT ) is a small cap, clinical-stage biotech company based in South San Francisco, California that develops oral tablet vaccines to protect against infectious diseases caused by coronavirus, norovirus, seasonal influenza, respiratory syntactical virus (RSV), and...

Shares of biopharmaceutical company Emergent BioSolutions   (NYSE: EBS) gained 46.6% in the first half of 2020 (January to June), according to data from S&P Global Market Intelligence . The S&P 500 returned negative 3.1% over the period. In 2020, the stock is up 55.9% through ...

If you had bought Novavax   (NASDAQ: NVAX) stock at the beginning of the year, you would be a happy investor right now. Shares of this biotech company have skyrocketed by almost 2,000% year to date, a rare feat even within the volatile biotech industry. Novavax has been able to achieve th...

For investors seeking to turn a modest initial investment into millions, explosive growth is desirable. And unexpectedly explosive growth is exactly why many healthcare investors are now looking at the vaccine start-up Vaxart (NASDAQ: VXRT) with newfound appreciation.  Vaxart's stock ...

Investors are apparently reacting to Pfizer and BioNTech's release of encouraging preliminary early-stage data on COVID-19 vaccine candidate BNT162b1 that showed significant jumps in neutralizing antibodies compared to convalescent plasma. More news on: AstraZeneca PLC, GlaxoSmithKline p...

The FDA has released guidance on its standards for approving a COVID-19 vaccine, including a requirement that it must demonstrate that it is at least 50% more effective than placebo (a low bar compared to vaccines for other infectious diseases). More news on: AstraZeneca PLC, GlaxoSmithK...

More vaccine news to catch up on - previous updates and specific topic posts on this subject were on June 15 , on June 11 , on May 26, on May 18 (with two other posts), on May 14, on May 1, on April 23, and on April 15 (author's note: yikes). Keep in mind that some of those posts were update...

OncoCyte (NYSEMKT: OCX )  -46%  following unsuccessful results from a clinical validation study of DetermaDx. More news on: OncoCyte Corporation, Zynerba Pharmaceuticals, Inc., Liquidia Technologies, Inc., Stocks on the move, , Read more ...

Shares of Vaxart (NASDAQ: VXRT) were vaulting 10.8% higher as of 11:38 a.m. EDT on Monday after rising as much as 22.9% earlier in the day. The gain appears to be continued momentum from last Friday , when Vaxart's COVID-19 vaccine was selected to participate in the U.S. government's Operat...

Last week, the top-performing biotech stocks had something in common and by now you can probably guess exactly what that was. You got it. They both delivered positive press releases regarding their respective coronavirus vaccine candidates. Data source: Yahoo! Finance. Continue reading